Lilly wins European Alzheimer’s approval for Kisunla after regulatory setbacks
The anti-amyloid monoclonal antibody is part of the class of medicines representing the first disease-modifying therapies for the neurodegenerative disease.
List view / Grid view
The anti-amyloid monoclonal antibody is part of the class of medicines representing the first disease-modifying therapies for the neurodegenerative disease.
The CHMP hands the cancer drug two new recommendations, and the FDA approves its subcutaneous use as Keytruda Qlex.
EMA advisors at the CHMP backed the combination treatment and also recommended Bayer’s menopause drug Lynkuet, putting both on the path to being licensed.
This in-depth focus features articles on rapid microbiological methods, quality control, and using AI to read agar plates.
From groundbreaking cell and gene therapies to cost-effective drug delivery innovations, Europe is emerging as a hub for life-changing therapies. Explore expert insights and innovative solutions shaping the pharmaceutical industry.
EPR Issue 3 includes articles on microbiology, downstream processing, manufacturing, drug formulation and more.
The medicine becomes the first EU-approved oral treatment for adults who have postpartum depression (PPD).
The innovation is set to change how eligible bladder cancer patients in the US are treated who are unresponsive to traditional therapy.
As an important policy tool, the new editions by the WHO mark a “significant” step in broadening access to new medicines with proven clinical benefits.
The regulator’s new principles aim to ease the pathway to regulatory approval for rare disease drug developers in the US.
CE mark for Contivue platform supports its ambitions for Susvimo in age-related macular degeneration (AMD).
Significant investment in advanced technologies Is expected to support global adoption of mass spectrometry in the next five years.
European Parliament's SANT Committee urges for greater control on medicine provisions to help strengthen security of supply.
First-of-its-kind case continues EMA and MHRA harmonisation, streamlining the global biosimilar approval pathway.
And Eli Lilly and Company’s new oral GLP-1 obesity therapy orforglipron shines in late-phase clinical trials.